Format
Items per page
Sort by

Send to:

Choose Destination

Results: 1 to 20 of 424

1.

Neural correlates of adherence to extended-release naltrexone pharmacotherapy in heroin dependence.

Wang AL, Elman I, Lowen SB, Blady SJ, Lynch KG, Hyatt JM, O'Brien CP, Langleben DD.

Transl Psychiatry. 2015 Mar 17;5:e531. doi: 10.1038/tp.2015.20.

2.

Naltrexone vs Placebo for the Treatment of Alcohol Dependence: A Randomized Clinical Trial.

Oslin DW, Leong SH, Lynch KG, Berrettini W, O'Brien CP, Gordon AJ, Rukstalis M.

JAMA Psychiatry. 2015 Mar 11. doi: 10.1001/jamapsychiatry.2014.3053. [Epub ahead of print]

PMID:
25760804
3.

High-throughput oncogene mutation profiling shows demographic differences in BRAF mutation rates among melanoma patients.

van den Hurk K, Balint B, Toomey S, O'Leary PC, Unwin L, Sheahan K, McDermott EW, Murphy I, van den Oord JJ, Rafferty M, FitzGerald DM, Moran J, Cummins R, MacEneaney O, Kay EW, O'Brien CP, Finn SP, Heffron CC, Murphy M, Yela R, Power DG, Regan PJ, McDermott CM, O'Keeffe A, Orosz Z, Donnellan PP, Crown JP, Hennessy BT, Gallagher WM.

Melanoma Res. 2015 Mar 5. [Epub ahead of print]

PMID:
25746038
4.

Limitations of the use of the MP-RAGE to identify neural changes in the brain: recent cigarette smoking alters gray matter indices in the striatum.

Franklin TR, Wetherill RR, Jagannathan K, Hager N, O'Brien CP, Childress AR.

Front Hum Neurosci. 2015 Jan 28;8:1052. doi: 10.3389/fnhum.2014.01052. eCollection 2014. No abstract available.

5.

Extended-release naltrexone to prevent relapse among opioid dependent, criminal justice system involved adults: Rationale and design of a randomized controlled effectiveness trial.

Lee JD, Friedmann PD, Boney TY, Hoskinson RA Jr, McDonald R, Gordon M, Fishman M, Chen DT, Bonnie RJ, Kinlock TW, Nunes EV, Cornish JW, O'Brien CP.

Contemp Clin Trials. 2015 Mar;41:110-7. doi: 10.1016/j.cct.2015.01.005. Epub 2015 Jan 17.

PMID:
25602580
6.

Brief report: "spiders-No, puppies-Go", introducing a novel Go NoGo task tested in inner city adolescents at risk for poor impulse control.

Goldman M, Ehrman RN, Suh JJ, Hurt H, Marquez K, Franklin TR, O'Brien CP, Childress AR.

J Adolesc. 2015 Jan;38:45-8. doi: 10.1016/j.adolescence.2014.10.007. Epub 2014 Nov 24. No abstract available.

PMID:
25460679
7.

Interview with Eddy Award Winner Charles O'Brien, MD, PhD.

O'Brien CP, Denis C.

Drug Alcohol Depend. 2014 Oct 1;143:281-2. No abstract available.

PMID:
25343165
8.

A pilot trial of injectable, extended-release naltrexone for the treatment of co-occurring cocaine and alcohol dependence.

Pettinati HM, Kampman KM, Lynch KG, Dundon WD, Mahoney EM, Wierzbicki MR, O'Brien CP.

Am J Addict. 2014 Nov-Dec;23(6):591-7. doi: 10.1111/j.1521-0391.2014.12146.x. Epub 2014 Sep 22.

PMID:
25251201
9.

Moving internet gaming disorder forward: A reply.

Petry NM, Rehbein F, Gentile DA, Lemmens JS, Rumpf HJ, Mößle T, Bischof G, Tao R, Fung DS, Borges G, Auriacombe M, GonzálezIbáñez A, Tam P, O'Brien CP.

Addiction. 2014 Sep;109(9):1412-3. doi: 10.1111/add.12653. No abstract available.

PMID:
25103100
10.

Internet gaming and addiction: a reply to King & Delfabbro.

Petry NM, Rehbein F, Gentile DA, Lemmens JS, Rumpf HJ, Mößle T, Bischof G, Tao R, Fung DS, Borges G, Auriacombe M, GonzálezIbáñez A, Tam P, O'Brien CP.

Addiction. 2014 Sep;109(9):1567-8. doi: 10.1111/add.12549. Epub 2014 Apr 14. No abstract available.

PMID:
24724947
11.

Nipping cue reactivity in the bud: baclofen prevents limbic activation elicited by subliminal drug cues.

Young KA, Franklin TR, Roberts DC, Jagannathan K, Suh JJ, Wetherill RR, Wang Z, Kampman KM, O'Brien CP, Childress AR.

J Neurosci. 2014 Apr 2;34(14):5038-43. doi: 10.1523/JNEUROSCI.4977-13.2014.

12.

Managing patients with a history of substance abuse.

O'Brien CP.

Can Fam Physician. 2014 Mar;60(3):248-50. No abstract available.

13.

Molecular testing in oncology: problems, pitfalls and progress.

O'Brien CP, Taylor SE, O'Leary JJ, Finn SP.

Lung Cancer. 2014 Mar;83(3):309-15. doi: 10.1016/j.lungcan.2013.12.010. Epub 2014 Jan 3. Review.

PMID:
24472389
14.

An international consensus for assessing internet gaming disorder using the new DSM-5 approach.

Petry NM, Rehbein F, Gentile DA, Lemmens JS, Rumpf HJ, Mößle T, Bischof G, Tao R, Fung DS, Borges G, Auriacombe M, González Ibáñez A, Tam P, O'Brien CP.

Addiction. 2014 Sep;109(9):1399-406. doi: 10.1111/add.12457. Epub 2014 Jan 23.

PMID:
24456155
15.

Conversation with Charles P. O'Brien.

O'Brien CP.

Addiction. 2014 Apr;109(4):530-7. doi: 10.1111/add.12318. Epub 2014 Jan 17. No abstract available.

PMID:
24433275
16.

The dopamine receptor D2 (DRD2) SNP rs1076560 is associated with opioid addiction.

Clarke TK, Weiss AR, Ferarro TN, Kampman KM, Dackis CA, Pettinati HM, O'brien CP, Oslin DW, Lohoff FW, Berrettini WH.

Ann Hum Genet. 2014 Jan;78(1):33-9. doi: 10.1111/ahg.12046. Epub 2013 Nov 25.

17.

Aberrant behaviors in a primary care-based cohort of patients with chronic pain identified as misusing prescription opioids.

Cheatle MD, O'Brien CP, Mathai K, Hansen M, Grasso M, Yi P.

J Opioid Manag. 2013 Sep-Oct;9(5):315-24. doi: 10.5055/jom.2013.0174.

PMID:
24353044
18.

Predictive values for molecular diagnostics: converting unknown unknowns to known unknowns.

O'Brien CP, Langabeer SE, O'Byrne KJ, O'Leary JJ, Finn SP.

Mol Diagn Ther. 2014 Feb;18(1):1-4. doi: 10.1007/s40291-013-0076-x. No abstract available.

PMID:
24338436
19.

The impact of Dutch and Flemish scientists on the progress of addiction medicine.

O'Brien CP.

Tijdschr Psychiatr. 2013;55(11):821. No abstract available.

20.

Neural responses to subliminally presented cannabis and other emotionally evocative cues in cannabis-dependent individuals.

Wetherill RR, Childress AR, Jagannathan K, Bender J, Young KA, Suh JJ, O'Brien CP, Franklin TR.

Psychopharmacology (Berl). 2014 Apr;231(7):1397-407. doi: 10.1007/s00213-013-3342-z. Epub 2013 Nov 2.

PMID:
24186078
Format
Items per page
Sort by

Send to:

Choose Destination

Supplemental Content

Loading ...
Write to the Help Desk